The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized,Placebo-Controlled Pilot Clinical Trial
Restricted accessResearch articleFirst published online August, 2019
The Effect of Atorvastatin on Vascular Function and Structure in Young Adult Survivors of Childhood Cancer: A Randomized,Placebo-Controlled Pilot Clinical Trial
Many adult survivors of childhood cancer are at high-risk of developing cardiovascular disease. Cancer therapy may cause damage to the vascular endothelium, thereby initiating atherosclerosis. Atorvastatin has been shown to improve endothelial function independent of reducing cholesterol, as well as reduce/slow arterial stiffness and thickening, yet has never been studied in childhood cancer survivors (CCS).
Methods:
Twenty-seven young adult (age 26.8 ± 6.2 years) survivors of childhood acute lymphoblastic leukemia or Non-Hodgkin's lymphoma were randomly assigned (1:1) 40 mg/day of atorvastatin or placebo for 6 months. Brachial artery flow-mediated dilation (FMD), small artery reactive hyperemia index (RHI), arterial stiffness, and carotid artery elasticity/thickness were assessed.
Results:
Fifteen participants completed the trial. No significant treatment effect for any vascular outcomes was observed at 6 months; however, a significant decrease in peak FMD (−3.0 [95% confidence interval [CI]: −5.3, −0.7]) and a trending significant decrease in RHI (−0.3 [95% CI: −0.62, 0.01]) was observed in the placebo group, resulting in a trend toward a treatment effects (p < 0.10). No effect on arterial stiffness, carotid arterial elasticity, or thickness was observed.
Conclusion:
Six months of atorvastatin treatment did not improve endothelial function or arterial stiffness in young adult CCS. While a trend toward an improvement in endothelial function was present, findings should be interpreted with caution owing to the small number of evaluable participants and subsequent lack of sufficient power. Further research in a larger sample size is needed to fully elucidate the effects of atorvastatin on vascular function. Trial registered at clinicaltrials.gov as NCT01733953.
Get full access to this article
View all access options for this article.
References
1.
RiesLAG, SmithMA, GurneyJG, et al.Cancer incidence and survival among children and adolescents: United States SEER program 1975–1995. SEER Pediatric Monograph. Bethesda, MD: Nattional Cancer Institute;. 1999.
2.
SmithMA, RiesLAG. Childhood cancer: incidence, survival, and mortality. In: PizzoPAI, PoplackDG (Eds). Principles and practice of pediatric oncology (fourth edition). Philadelphia, PA: Lippincott Williams and Wilkins; 2002; pp. 1–12.
3.
RiesLAG, EisnerMP, KosaryCL. SEER cancer statistics review 1975–2000. Bethesda, MD: National Cancer Institute; 2003.
4.
LinaberyAM, RossJA. Childhood and adolescent cancer survival in the US by race and ethnicity for the diagnostic period 1975–1999. Cancer. 2008; 113(9):2575–96.
5.
OeffingerKC, MertensAC, SkylarCA, et al.Chronic health conditions in adult survivors of childhood cancer. N Engl J Med. 2006; 355:1572–82.
6.
GurneyJG, NessKK, StovallM, et al.Final height and body mass index among adult survivors of childhood brain cancer: childhood cancer survivor study. J Clin Endocrinol Metab. 2003; 88(10):4731–9.
7.
NandagopalR, LaverdiereC, MulrooneyD, et al.Endocrine late effects of childhood cancer therapy: a report from the Children's Oncology Group. Horm Res. 2008; 69:65–74.
8.
MertensAC, YasuiY, NegliaJP, et al.Late mortality experience in five-year survivors of childhood and adolescent cancer: the Childhood Cancer Survivor Study. J Clin Oncol. 2001; 19(13):3163–72.
9.
OeffingerKC, BuchananGR, EshelmanDA, et al.Cardiovascular risk factors in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2001; 23(7):424–30.
10.
BowersDC, LiuY, LeisenringW, et al.Late-occurring stroke among long-term survivors of childhood leukemia and brain tumors: a report from the Childhood Cancer Survivor Study. J Clin Oncol. 2006; 24:5277–82.
11.
MulrooneyDA, YeazelMW, KawashimaT, et al.Cardiac outcomes in a cohort of adult survivors of childhood and adolescent cancer: retrospective analysis of the Childhood Cancer Survivor Study cohort. Br Med J. 2009; 339:b4606.
12.
MoleskiM. Neuropsychological, neuroanatomatical, and neurophysiological consequences of CNS chemotherapy for acute lymphoblastic leukemia. Arch Clin Neuropsychol. 2000; 350:1535–48.
13.
KaemingkKI, CareyME, MooreIMK, et al.Math weaknesses in survivors of acute lymphoblastic leukemia compared to healthy children. Child Neuropsychol. 2004; 10:14–23.
14.
AndersonF, Kunin-BatsonA. Neurocognitive late effects of chemotherapy in children: the past 10 years of research on brain structure and function. Pediatr Blood Cancer. 2009; 52:159–64.
15.
MertensAC. Cause of mortality in 5-year survivors of childhood cancer. Pediatr Blood Cancer. 2007; 48(7):723–6.
16.
LüscherTF, BartonM. Biology of the endothelium. Clin Cardiol. 1997; 20(Suppl II):II3–10.
17.
KinlayS, LibbyP, GanzP. Endothelial function and coronary artery disease. Curr Opin Lipidol. 2001; 12:383–9.
18.
DrexlerH. Factors involved in the maintenance of endothelial function. Am J Cardiol. 1998; 82:3S–4S.
19.
HalcoxJPJ, DeanfieldJE. Endothelial cell function testing: how does the method help us in evaluating vascular status?. Acta Paediatr Suppl. 2004; 446:48–54.
20.
DengelDR, NessKK, GlasserSP, et al.Endothelial function in young adult survivors of childhood acute lymphoblastic leukemia. J Pediatr Hematol Oncol. 2008; 30(1):20–5.
21.
DengelDR, KellyAS, ZhangL, et al.Signs of early sub-clinical atherosclerosis in childhood cancer survivors. Pediatr Blood Cancer. 2014; 61:532–7.
22.
CelermajerD, SorensenK, GoochV, et al.Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet. 1992; 340:1111–5.
23.
DeanfieldJE, HalcoxJP, RabelinkTJ. Endothelial function and dysfunction: testing and clinical relevance. Circulation. 2007; 115:1285–95.
24.
StoneN, RobinsonJ, LichtensteinA, et al.2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol. 2013; 1–84.
25.
RerianiMK, DunlaySM, GuptaB, et al.Effects of statins on coronary and peripheral endothelial function in humans: a systematic review and meta-analysis of randomized controlled trials. Eur J Cardiovasc Prev Rehabil. 2011; 18(5):704–16.
26.
MatsunoH, TakeiM, HayashiH, et al.Simvastatin enhances the regeneration of endothelial cells via VEGF secretion in injured arteries. J Cardiovasc Pharmacol. 2004; 43:333–40.
27.
OtaH, EtoM, KanoM, et al.Induction of endothelial nitric oxide synthase, SIRT1, and catalase by statins inhibits endothelial senescence through the Akt pathway. Arterioscler Thromb Vasc Biol. 2010; 30:2205–11.
28.
AxelDI, RiessenR, RungeH, et al.Effects of cerivastatin on human arterial smooth muscle cell proliferation and migration in transfilter cocultures. J Cardiovasc Pharmacol. 2000; 35(4):619–29.
29.
OrrJS, DengoAL, RiveroJM, et al.Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults. Hypertension. 2009; 54(4):763–8.
30.
RatchfordEV, GutierrezJ, LorenzoD, et al.Short-term effect of atorvastatin on carotid artery elasticity: a pilot study. Stroke. 2011; 42(12):3460–4.
31.
RidkerPM, DanielsonE, FonsecaFA, et al.Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med. 2008; 359(21):2195–207.
32.
SuzumuraK, YasuharaM, TanakaK, et al.An in vitro study of the hydroxyl radical scavenging property of fluvastatin, an HMG-CoA reductase inhibitor. Chem Pharm Bull. 1999; 47:1010–2.
33.
RikitakeY, KawashimaS, TakeshitaS, et al.Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 2001; 154:87–96.
34.
SinghU, DevarajS, JialalI, et al.Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol. 2008; 102(3):321–5.
35.
FrisonL, PocockSJ. Repeated measures in clinical trials: analysis using mean summary statistics and its implications for design. Stat Med. 1992; 11:1685–704.
36.
SennS. Change from baseline and analysis of covariance revisited. Stat Med. 2006; 25:4334–44.
37.
BauPFD, BauCHD, NaujorksAA, et al.Diurnal variation of vascular diameter and reactivity in healthy young men. Braz J Med Biol Res. 2008; 41:500–3.
38.
KolliasGE, StamatelopoulosKS, PapaioannouTG, et al.Diurnal variation of endothelial function and arterial stiffness in hypertension. J Hum Hypertens. 2009; 23:597–604.
39.
OttoME, SvatikovaA, BarrettoRB, et al.Early morning attenuation of endothelial function in healthy humans. Circulation. 2004; 109:2507–10.
40.
MullerJE, ToflerGH, VerrierRL. Sympathetic activity as the cause of the morning increase in cardiac events: a likely culprit, but the evidence remains circumstantial. Circulation. 1995; 91:2508–9.
41.
HijmeringML, StroesES, OlijhoekJ, et al.Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J Am Coll Cardiol. 2002; 39:683–8.
42.
PanzaJA, EpsteinSE, QuyyumiAA. Circadian variation in vascular tone and its relation to alpha-sympathetic vasoconstrictor activity. N Engl J Med. 1991; 325:986–90.
43.
ToflerGH, BrezinskiD, SchaferAI, et al.Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med. 1987; 316:1514–8.
44.
PapaioannouTG, KaratzisEN, PapamichaelCM, et al.Circadian variation of arterial pressure wave reflections. Am J Hypertens. 2006; 19:259–63.
45.
BodlajG, BergJ, BiesenbachG. Diurnal variation of pulse wave velocity assessed non-invasively by applanation tonometry in young healthy men. Yonsei Med J. 2007; 48:665–70.
46.
ShankarS, MarinaN, HudsonM, et al.Monitoring for cardiovascular disease in survivors of childhood cancer: report from the Cardiovascular Disease Task Force of the Children's Oncology Group. Pediatrics. 2008; 121:e387–e396.
47.
BuizerA, de SonnevilleL, van den Heuvel-EibrinkM, et al.Chemotherapy and attentional dysfunction in survivors of childhood acute lymphoblastic leukemia: effect of treatment intensity. Pediatr Blood Cancer. 2005; 45:281–90.
48.
van der PalH, van DalenE, HauptmannM, et al.Cardiac function in 5-year survivors of childhood cancer: a long-term follow-up study. Arch Intern Med. 2010; 170:1247–55.
